title: [Platelet activation in cardiology: methods, indications and therapeutic perspectives].
abstract: Platelet activation and/or platelet reactivity have been reported to be associated with coronary heart disease. Whole blood flow cytometry allows to analyze platelets in their physiological environment, while other assays need platelet separation, susceptible to induce platelet modifications. But flow cytometric assay also have limitations. We studied preanalytical conditions in healthy volunteers, using two monoclonal antibodies directed against CD62 and CD63 (two specific markers of platelet degranulation), and two markers which recognize GPIIb/IIIa activation (PAC1 and bound fibrinogen). Preanalytical requirements were as follow: 1) whole blood samples need antagonists of platelet activation i.e., a mixture of theophylline, adenosine and dipyridamole, since artefactual platelet activation rapidly occurred in citrated whole blood, 2) whole blood should be immediately immunolabeled when samples arrived to laboratory, because fixation did not prevent artefactual time dependent activation, 3) the stability of immunolabeling was determined for each monoclonal antibody: paraformaldehyde as fixative solution was mandatory for both CD62 and CD63, whereas it enhanced bound fibrinogen and PAC1 expression, 4) platelets can be easily identified and gating on a dual scatter (forward scatter x side scatter) dot plot with no specified labeling. The whole blood flow cytometric assay must be standardized in future clinical studies, especially regarding to preanalytical requirements.
authors.affiliation: Laboratoire Central d'Hématologie, CHU Robert Debré, Reims.
authors.forename: N
authors.initials: N
authors.lastname: Hézard
authors.forename: D
authors.initials: D
authors.lastname: Metz
authors.forename: G
authors.initials: G
authors.lastname: Simon
authors.forename: C
authors.initials: C
authors.lastname: Droullé
authors.forename: S
authors.initials: S
authors.lastname: Daliphard
authors.forename: G
authors.initials: G
authors.lastname: Potron
mesh_terms: D000241:Adenosine / Q000494:pharmacology; D000244:Adenosine Diphosphate / Q000494:pharmacology; D015703:Antigens, CD / Q000032:analysis / Q000097:blood*; D001792:Blood Platelets / Q000502:physiology*; D023201:CD40 Ligand; D003327:Coronary Disease / Q000097:blood* / Q000175:diagnosis / Q000628:therapy; D004176:Dipyridamole / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D008024:Ligands; D008562:Membrane Glycoproteins / Q000494:pharmacology / Q000502:physiology; D019007:P-Selectin / Q000097:blood; D015539:Platelet Activation / Q000187:drug effects; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000032:analysis; D010980:Platelet Membrane Glycoproteins / Q000032:analysis; D012016:Reference Values; D060149:Tetraspanin 30; D013806:Theophylline / Q000494:pharmacology
chemical_list: D015703:Antigens, CD; C554586:CD63 protein, human; D008024:Ligands; D008562:Membrane Glycoproteins; D019007:P-Selectin; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D010980:Platelet Membrane Glycoproteins; D060149:Tetraspanin 30; D023201:CD40 Ligand; D000244:Adenosine Diphosphate; D004176:Dipyridamole; D013806:Theophylline; D000241:Adenosine
vernacular_title: Activation plaquettaire en cardiologie: méthodes, indications et perspectives thérapeutiques.